A Green WAVE Will Happen, TRUMP Will Legalize Cannabis
$Tilray Brands (TLRY.US)$
$Tilray Brands (TLRY.US)$ TLRY offers more upside reward than downside risk at current levels. TLRY is growing revenues & is trading well below it's book value of $3.97 a share, it has unfairly seen a decline in price while being fully lumped in with the cannabis sector. TLRY brings is revenues from it's bever...

$EVgo Inc (EVGO.US)$  Our Chart program alert shows a pull back below $6 within next 5 trading days is 70% likely.

$Tilray Brands (TLRY.US)$
$Tilray Brands (TLRY.US)$ TLRY offers more upside reward than downside risk at current levels. TLRY is growing revenues & is trading well below it's book value of $3.97 a share, it has unfairly seen a decline in price while being fully lumped in with the cannabis sector. TLRY brings is revenues from it's beverages at a growing rate. Earlier in 2024 insiders bought substantial amount of shares on the open market in the...

$FuboTV (FUBO.US)$ We are reviewing FUBO T.V and we believe the current stock price doesn't reflect the true value. We believe a speculative investment in FUBO now offers more upside reward than downside risk.  
FUBO operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. The company's platform allows customers to acce...

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns   $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech     $Esperion Therapeutics (ESPR.US)$  Esper...

$Tilray Brands (TLRY.US)$ TLRY offers more upside reward than downside risk at current levels. TLRY is growing revenues & is trading well below it's book value of $3.97 a share, it has unfairly seen a decline in price while being fully lumped in with the cannabis sector.
TLRY is a lifestyle consumer products company that engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United St...

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns   $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech   $Esperion Therapeutics (ESPR.US)$  Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...

$FuboTV (FUBO.US)$ We are reviewing FUBO T.V and we believe the current stock price doesn't reflect the true value. We believe a speculative investment in FUBO now offers more upside reward than downside risk.  
FUBO operates a live TV streaming platform for live sports, news, and  entertainment content in the United States and internationally. The  company's platform allows customers to access content through s...

$Esperion Therapeutics (ESPR.US)$ An Investment Now In This Company Should Return 10 X Your Money.
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech   $Esperion Therapeutics (ESPR.US)$  Esperion has the only FDA approved statin al...